Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
Express News | Altimmune: To File Ind Applications for Pemvidutide in up to 3 Additional Indications With First of These Ind Submissions in Q4